2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14824
    Sofiniclin 799279-80-4
    Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD).
    Sofiniclin
  • HY-15071
    YM90K 154164-30-4 98.32%
    YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions.
    YM90K
  • HY-15086
    Selfotel 110347-85-8 99.67%
    Selfotel (CGS 19755) is a selective and competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptor. CGS 19755 inhibits the binding of [3H]-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to NMDA-type receptors with an IC50 of 50 nM.
    Selfotel
  • HY-15476
    VU 0364439 1246086-78-1 99.42%
    VU 0364439 is a mGlu4 positive allosteric modulator with an EC50 of 19.8 nM. VU 0364439 modulates the GRM4/CBX4/HIF-1α signaling pathway by enhancing GRM4-CBX4 interaction. VU 0364439 can be used for the research of parkinson’s disease.
    VU 0364439
  • HY-16579
    Etifoxine hydrochloride 56776-32-0 99.83%
    Etifoxine hydrochloride, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine hydrochloride reveals anxiolytic and anticonvulsant properties in rodents.
    Etifoxine hydrochloride
  • HY-16636
    ML337 1443118-44-2 99.04%
    ML337 is a selective and brain-penetrant negative allosteric modulator of mGlu3, with an IC50 of 593 nM. ML337 possesses a favorable dystrophia myotonica protein kinase (DMPK) and ancillary pharmacology profile. ML337 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ML337
  • HY-16728
    Rapastinel 117928-94-6 99.78%
    Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma.
    Rapastinel
  • HY-18715
    Ornidazole (Levo-) 166734-83-4 98.86%
    Levo-ornidazole ((S)-Ornidazole) is the L-isomer of Ornidazole. Ornidazole (Levo-) increases GAD 65/67 expression and decreases brain Glu/GABA ratio. Ornidazole (Levo-) has a mild sedative effect. Levo-ornidazole can be used in the research of anti-anaerobic and anti-parasitic agents.
    Ornidazole (Levo-)
  • HY-19123
    Z-321 130849-58-0 99.72%
    Z-321 is a prolylendopeptidase (PEP) inhibitor.
    Z-321
  • HY-19477
    SB-616234-A 908601-49-0 99.40%
    SB-616234-A is a selective and orally bioavailable 5-HT1B receptor antagonist, with anxiolytic and antidepressant activity.
    SB-616234-A
  • HY-19661
    Tecadenoson 204512-90-3 99.69%
    Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist.
    Tecadenoson
  • HY-22183
    Anticonvulsant agent 3 59565-51-4 99.64%
    Anticonvulsant agent 3 is a 2-amino derivative with anticonvulsant activity[1].
    Anticonvulsant agent 3
  • HY-50882
    ELN318463 851600-86-7 99.45%
    ELN318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN318463 is 51-fold more selective for PS1.
    ELN318463
  • HY-65036
    4-Bromo-2-hydroxypyridine 36953-37-4 ≥98.0%
    4-Bromo-2-hydroxypyridine is an intermediate. 4-Bromo-2-hydroxypyridine can be used to synthesize M1 muscarinic acetylcholine receptor (M1 mAChR) positive allosteric modulators. 4-Bromo-2-hydroxypyridine can be used in the research of Alzheimer's disease and schizophrenia.
    4-Bromo-2-hydroxypyridine
  • HY-77491
    FAAH/MAGL-IN-5 1010096-65-7
    AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC50: 1.2 nM) with neuroprotective effects.
    FAAH/MAGL-IN-5
  • HY-A0135
    Enflurane 13838-16-9 ≥98.0%
    Enflurane, a volatile anaesthetic, is a potent inhibitor of high conductance Ca2+-activated K+ channels of Chara australis. Enflurane is an internal standard in monitoring halogenated volatile anaesthetics by headspace gas chromatography-mass spectrometry.
    Enflurane
  • HY-A0151
    Thioproperazine 316-81-4 98.76%
    Thioproperazine (RP 7843) is an orally active antipsychotic agent with calming, antiemetic activity. Thioproperazine is effective in promoting the release of dopamine in rat striatum. Thioproperazine can be used in studies of schizophrenia and bipolar disorder.
    Thioproperazine
  • HY-B0459
    Scopine 498-45-3 98.0%
    Scopine is a metabolite of Scopolamine (HY-N0296) and brain-targeting compound. Scopine significantly increases the brain exposure of Chlorambucil (HY-13593) and enhances its anti-glioma activity. Scopine can be used in targeted therapy research for brain gliomas.
    Scopine
  • HY-B0516
    Articaine hydrochloride 23964-57-0 99.38%
    Articaine (Hoe-045) hydrochloride is a selective inhibitor of voltage-gated sodium channels (such as rNav1.4, hNav1.7, and rNav1.8), with an IC50 of 15.8 μM for open-state Na+ channels, and IC50 of 40.6 μM and 378 μM for inactivated and resting-state Na+ channels, respectively. Articaine hydrochloride exerts local anesthetic activity by inhibiting Na+ influx to block nerve impulse conduction, and can also inhibit NF-κB activation and NLRP3 inflammasome pathways, exhibiting anti-inflammatory function. Articaine hydrochloride can be used in the study of dental local anesthesia and inflammatory-related diseases (such as acute kidney injury).
    Articaine hydrochloride
  • HY-B0830
    Isoprocarb 2631-40-5 99.12%
    Isoprocarb is carbamate insecticide that widely used to control rice paddy lice and leafhopper. Isoprocarb is also an AChE inhibitor.
    Isoprocarb
Cat. No. Product Name / Synonyms Application Reactivity